
    
      References

        1. World Health Organization. Influenza A (H1N1) - update 95 [cited 2010 April 10].
           Available from http://www.who.int/csr/don/2009_12_30/en/index.html

        2. Echevarria-Zuno S, Mejia-Arangure JM, Mar-Obeso AJ, et al. Infection and death from
           influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 2009; 374: 2072-9.

        3. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization
           due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302:
           1896-902.

        4. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in
           the United States, April-June 2009. N Engl J Med 2009; 361:1935-44.

        5. Chen H, Cheung CL, Tai H, et al. Oseltamivir-resistant influenza A pandemic (H1N1) 2009
           virus, Hong Kong, China. Emerg Infect Dis 2009;15:1970-2.

        6. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, et al. Safety and efficacy of a
           novel microneedle device for dose sparing intradermal influenza vaccination in healthy
           adults. Vaccine 2009;27:454-9

        7. Myers CA, Faix DJ, Blair PJ. Possible reduced effectiveness of the 2009 H1N1 component
           of live, attenuated influenza vaccine. Clin Infect Dis. 2011;15;53:207-8.9.

        8. Roukens R, Vossen AC, Boland GJ, et al. Intradermal hepatitis B vaccination in
           non-responders after topical application of imiquimod (Aldara). Vaccine 2010;4288-4293.

        9. Tyring S, Conant M, Marini M, Van Der Meijden W, Washenik K. Imiquimod, an international
           update on therapeutic uses in dermatology. Int J Dermatol 2002;41(11):810-6.

       10. Burns Jr RP, Ferbel B, Tomai M, Miller R, Gaspari AA. The imidazoquinolines, imiquimod
           and R-848, induce functional, but not phenotypic, maturation of human epidermal
           Langerhans' cells. Clin Immunol 2000;94(1):13-23.

       11. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, et al. Imiquimod, a topical
           immune response modifier, induces migration of Langerhans cells. J Invest Dermatol
           2000;114(1):135-41.

       12. Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP. Imiquimod and resiquimod in a mouse
           model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery.
           Vaccine 2004;22(13-14):1799-809.
    
  